The latest price target for Lucid Diagnostics (NASDAQ:LUCD) was reported by Ascendiant Capital on April 21, 2025. The analyst firm set a price target for $7.50 expecting LUCD to rise to within 12 months (a possible 499.95% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Lucid Diagnostics (NASDAQ:LUCD) was provided by Ascendiant Capital, and Lucid Diagnostics maintained their buy rating.

There is no last upgrade for Lucid Diagnostics

There is no last downgrade for Lucid Diagnostics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lucid Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lucid Diagnostics was filed on April 21, 2025 so you should expect the next rating to be made available sometime around April 21, 2026.

While ratings are subjective and will change, the latest Lucid Diagnostics (LUCD) rating was a maintained with a price target of $7.00 to $7.50. The current price Lucid Diagnostics (LUCD) is trading at is $1.25, which is out of the analyst’s predicted range.